References
- Centers for Disease Control and Prevention. Trends in ischemic heart disease mortality—United States, 1980–1988. MMWR Morb Mortal Wkly Rep 1992; 41(30):548–56
- Grodstein F, Stampfer MJ, Manson JE, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996; 335(7):453–61
- Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997; 336(25): 1769–75
- Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995; 273(3): 199–208 [Erratum, JAMA 1995; 274(21):1676]
- Peterson LR. Estrogen replacement therapy and coronary artery disease. Curt Opin Cardiol 1998: 13(4):223–31
- Rowe T, ed. Canadian Consensus Conference on Menopause and Osteoporosis. Hormone replacement therapy and cardiovascular disease. J Soc Obstet Gynaecol Can 1998; 20(13): 17–21
- Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999; 340(23): 1801–11
- Gerhard M, Walsh BW, Tawakol A, et al. Estradiol therapy combined with progesterone and endothelium-dependent vasodilation in postmenopausal women. Circulation 1998; 98(12): 1158–63
- Ridker PM, Hennekens CH, Rifai N, et al. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 1999; 100(7):713–6
- Schunkert H, Danser AH, Hense H, et al. Effects of estrogen replacement on the renin-angiotensin system in postmenopausal women. Circulation 1997; 95(1):39–45
- Lim WK, Wren B, Jepson N, et al. Effect of hormone replacement therapy on left ventricular hypertrophy. Am J Cardiol 1999; 83(7):1132–4
- Krasinski K, Spyridopoulos I, Asahara T, et al. Estradiol accelerates functional endothelial recovery after arterial injury. Circulation 1997; 95(7): 1768–72
- Spyridopoulos I, Sullivan AB, Kearney M, et al. Estrogen- receptor-mediated inhibition of human endothelial cell apoptosis: estradiol as a survival factor. Circulation 1997; 95(6): 1505–14
- Abu-Halawa SA, Thompson K, Kirkeeide RL, et al. Estrogen replacement therapy and outcome of coronary balloon angioplasty in postmenopausal women. Am J Cardiol 1998; 82(4):409–13
- Anderson PW, Paul S, Shah A, et al. Raloxifene favorably alters serum lipids in postmenopausal women with cardiovascular risk factors. (Abstr) Circulation 1998; 98(17):I–7
- Koh KK, Cardillo C, Bui MN, et al. Vascular effects of estrogen and cholesterol-lowering therapies in hypercholesterolemic postmenopausal women. Circulation 1999; 99(3):354–60
- Walsh BW, Kuller LH, Wild RA, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998; 279(18): 1445–51
- Caulin-Glaser T, Farrell WJ, Pfau SE, et al. Modulation of circulating cellular adhesion molecules in postmenopausal women with coronary artery disease. J Am Coll Cardiol 1998; 31(7):1555–60
- Hemminki E, McPherson K. Impact of postmenopausal hormone therapy on cardiovascular events and cancer: pooled data from clinical trials. BMJ 1997; 315(7101): 149–153
- Hulley S, Grady D, Bush T, et al, for the Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280(7):605–13
- Ridker PM, Buring JE, Shih J, et al. Prospective study of C- reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998; 98(8):731–3
- Sullivan JM, El-Zeky F, Vander Zwaag R, et al. Effect on survival of estrogen replacement therapy after coronary artery bypass grafting. Am J Cardiol 1997; 79(7):847–50
- Herrington DM, Reboussin DM, Klein KP, et al. The Estrogen Replacement and Atherosclerosis (ERA) study: study design and baseline characteristics of the cohort. Control Clin Trials 2000; 21(3):257–85
- Mosca L, Grundy SM, Judelson D, et al. AHA/ACC Scientific Statement: Consensus Panel Statement. Guide to preventive cardiology for women. J Am Coll Cardiol 1999; 33(6):1751–5
- Lewis SJ, Sacks FM, Mitchell JS, et al. Effect of pravastatin on cardiovascular events in women after myocardial infarction: the Cholesterol and Recurrent Events (CARE) trial. J Am Coll Cardiol 1998; 32(1): 140–6
- Paul S, Dean RA, Tracy RP, et al. Effects of raloxifene and hormone replacement therapy on homocysteine and C-reactive protein levels in postmenopausal women. (Abstr) Circulation 1998; 98(17):I–7